Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
NCT ID: NCT03048422
Last Updated: 2022-11-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
643 participants
INTERVENTIONAL
2018-01-19
2020-10-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
NCT01618305
Dolutegravir in Pregnant HIV Mothers and Their Neonates
NCT03249181
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
NCT01854762
DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women
NCT04808973
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns
NCT00000642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At study entry, mothers were randomly assigned to either receive DTG plus FTC/TAF (Arm 1), DTG plus FTC/TDF (Arm 2), or EFV/FTC/TDF (Arm 3) during pregnancy, through delivery, and for 50 weeks postpartum.
Mothers completed study visits at study entry and every four weeks during pregnancy. Study visits for mothers and their infants occurred at delivery and at 6, 14, 26, 38, and 50 weeks postpartum. Visits for mothers and infants included physical examinations and blood collection. Select study visits also included breast milk collection from mothers who breastfed, hair and urine collection, ultrasound scans, pregnancy testing, contraception counseling, and, for a subset of participants, dual energy x-ray absorptiometry (DXA) scans for mothers and their infants.
For pregnancy outcome measures, mothers and infants were evaluated together as mother-infant pairs, with any outcome between the two counting as an event (for example, if an infant was born small for gestational age, this would be a pregnancy outcome event for the mother-infant pair). For all other outcome measures, women and infants were evaluated separately.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Maternal DTG+FTC/TAF
Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
Dolutegravir
One 50 mg DTG tablet was administered orally once daily
Emtricitabine/tenofovir alafenamide
One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
Arm 2: Maternal DTG+FTC/TDF
Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
Dolutegravir
One 50 mg DTG tablet was administered orally once daily
Emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
Arm 3: Maternal EFV/FTC/TDF
Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
Efavirenz/emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
Arm 1 Infants
Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
No interventions assigned to this group
Arm 2 Infants
Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
No interventions assigned to this group
Arm 3 Infants
Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dolutegravir
One 50 mg DTG tablet was administered orally once daily
Emtricitabine/tenofovir alafenamide
One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
Emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
Efavirenz/emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mother has confirmed HIV-1 infection based on documented testing of two samples collected at different time points:
* Sample #1 may be tested using any of the following:
* Two rapid antibody tests from different manufacturers or based on different principles and epitopes
* One enzyme immunoassay (EIA) OR Western blot OR immunofluorescence assay OR chemiluminescence assay
* One HIV DNA polymerase chain reaction (PCR)
* One quantitative HIV RNA PCR (above the limit of detection of the assay)
* One qualitative HIV RNA PCR
* One total HIV nucleic acid test
* Sample #2 may be tested using any of the following:
* One rapid antibody test. If this option is used in combination with two rapid tests for Sample #1, at least one of the three rapid tests must be FDA-approved and the third rapid test must be from a third manufacturer or based on a third principle or epitope.
* One EIA OR Western blot OR immunofluorescence assay OR chemiluminescence assay
* One HIV DNA PCR
* One quantitative HIV RNA PCR (above the limit of detection of the assay)
* One qualitative HIV RNA PCR
* One total HIV nucleic acid test.
* See the protocol for more information on this inclusion criterion.
* At screening, mother is ART-naive, defined as having not received prior antiretroviral therapy other than ARVs received during prior pregnancies or prior periods of breastfeeding (i.e., receipt of any single, dual, or triple ARV regimen during prior time-limited periods of pregnancy and breastfeeding is permitted). Receipt of up to 14 days of ARVs during the current pregnancy is permitted prior to study entry so that initiation of ARVs during the current pregnancy is not delayed during the study screening period. Note: Non-study ART may be initiated in the current pregnancy prior to initiation of the study screening process. For eligible participants, enrollment must occur within 14 days of non-study ART initiation. Note: Receipt of ARVs during a prior pregnancy or prior period of breastfeeding must have concluded at least six months prior to study entry. Receipt of TDF or FTC/TDF for pre-exposure prophylaxis at any time in the past is not exclusionary (even if received within six months prior to study entry).
* At screening, mother has the following laboratory test results (based on testing of samples collected within 14 days prior to study entry):
* Grade 1 or lower (less than 2.5 times upper limit of normal \[ULN\]) alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
* Grade 2 or lower (less than or equal to 1.8 times ULN) creatinine
* Grade 2 or lower (greater than or equal to 60 mL/min) estimated creatinine clearance (CrCl; Cockcroft-Gault formula). See the protocol for guidance on severity grading. Laboratory tests may be repeated during the study screening period, with the latest result used for eligibility determination.
* At screening and at study entry, no evidence of multiple gestation or fetal anomalies, as assessed by best available method
* At study entry, gestational age of 14-28 weeks, defined as greater than 13 weeks plus six days and less than 28 completed weeks gestation, estimated by best available method. Note: For this inclusion criterion and the previous inclusion criterion, fetal ultrasound is preferred but not required for purposes of eligibility determination. If ultrasound cannot be performed during the study screening period prior to study entry, it must be performed within 14 days after study entry. As further explained in the protocol, enrolled participants will not be withdrawn from the study based on ultrasound findings obtained after study entry.
* At study entry, mother expects to remain in the geographic area of the study site during pregnancy and for 50 weeks postpartum \[Eligibility criteria added per Letter of Amendment 1 to V2; July 2018\]:
* At study entry, mother reports that she does not wish to become pregnant again for at least 50 weeks after her current pregnancy and that she is willing to use effective contraception during this period. Effective contraception may include surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy) or any of the following methods:
* Contraceptive intrauterine device (IUD) or intrauterine system (IUS)
* Subdermal contraceptive implant
* Progestogen injections
* Progestogen only oral contraceptive pills
* Combined estrogen and progestogen oral contraceptive pills
* Percutaneous contraceptive patches
* Contraceptive vaginal rings
* Note: IUDs, IUSs, implants, and injections are strongly recommended due to their lower failure rates with typical use. Male or female condom use is recommended with all contraceptive methods for dual protection against pregnancy and to avoid transmission of HIV and other sexually transmitted infections.
Exclusion Criteria
* Mother is currently receiving:
* A psychoactive medication for treatment of a psychiatric illness
* Treatment for active tuberculosis
* Treatment for active hepatitis C infection
* Mother is expected to require treatment with interferon and/or ribavirin for hepatitis C infection during the study follow-up period
* Mother has a history of any of the following, as determined by the site investigator or designee based on maternal report and available medical records:
* Hypersensitivity or clinically significant adverse reaction to any of the ARVs included in the three study drug regimens (ever)
* Antiretroviral drug resistance mutations that would impact selection of ART regimen (ever)
* Clinically significant heart disease and/or known prolonged corrected QT (QTc) interval (ever)
* Suicidal ideation or attempt (ever)
* HIV-2 infection (ever)
* Zika virus infection, diagnosed or suspected, during the current pregnancy
* Receipt of any antiretroviral medication within six months prior to study entry, with two exceptions: receipt of any duration of TDF or FTC/TDF for pre-exposure prophylaxis or receipt of up to 14 days of ARVs during the current pregnancy
* Receipt of any prohibited medication within 14 days prior to study entry (see the protocol for more information)
* Clinically significant acute illness requiring systemic treatment and/or hospitalization (i.e., major medical condition that is likely to lead to hospitalization and/or to an adverse pregnancy outcome) within 14 days prior to study entry
* Unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice) or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) within 14 days prior to study entry
* Note: Testing to rule out HIV-2 infection is not required.
* Mother or fetus has any other condition that, in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shahin Lockman, MD, MSc
Role: STUDY_CHAIR
Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital
Lameck Chinula, MBBS, MMED, FCOG
Role: STUDY_CHAIR
Kamuzu Central Hospital in Lilongwe, Malawi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ. of Florida Jacksonville NICHD CRS
Jacksonville, Florida, United States
Pediatric Perinatal HIV Clinical Trials Unit CRS
Miami, Florida, United States
Gaborone CRS
Gaborone, South-East District, Botswana
Molepolole CRS
Gaborone, , Botswana
SOM Federal University Minas Gerais Brazil NICHD CRS
Belo Horizonte, Minas Gerais, Brazil
Hospital Federal dos Servidores do Estado NICHD CRS
Rio de Janeiro, , Brazil
Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS
Rio de Janeiro, , Brazil
Hosp. Geral De Nova Igaucu Brazil NICHD CRS
Rio de Janeiro, , Brazil
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, India
Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa
Wits RHI Shandukani Research Centre CRS
Johannesburg, Gauteng, South Africa
Umlazi CRS
Durban, KwaZulu-Natal, South Africa
Famcru Crs
Tygerberg, Western Cape, South Africa
Kilimanjaro Christian Medical Centre (KCMC)
Moshi, , Tanzania
Siriraj Hospital ,Mahidol University NICHD CRS
Bangkok, Bangkoknoi, Thailand
Chiangrai Prachanukroh Hospital NICHD CRS
Chiang Mai, , Thailand
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
Chiang Mai, , Thailand
Baylor-Uganda CRS
Kampala, , Uganda
Seke North CRS
Chitungwiza, , Zimbabwe
St Mary's CRS
Chitungwiza, , Zimbabwe
Harare Family Care CRS
Harare, , Zimbabwe
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, Joao E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J; IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7.
Masheto G, Brummel SS, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L, Coletti A, Mukura D, Rossouw L, Theron G, Krotje C, Jean-Philippe P, Chakhtoura N, Cassim H, Mathiba SR, Maena J, Murtaugh W, Fairlie L, Currier J, Hoffman R, Chinula L, Sax PE, Stranix-Chibanda L, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial. J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):172-179. doi: 10.1097/QAI.0000000000003478.
Eke AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, Eleje GU, Ezebialu IU, Korutaro V, Wabwire D, Matubu A, Mbengeranwa T, Chakhtoura N, Chinula L, McCarthy K, Knowles K, Krotje C, Linton MF, Dooley KE, Sax PE, Brown T, Lockman S; IMPAACT 2010/VESTED Study Team. Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy. Clin Infect Dis. 2025 Mar 17;80(3):594-601. doi: 10.1093/cid/ciae441.
Jacobson DL, Crider KS, DeMarrais P, Brummel S, Zhang M, Pfeiffer CM, Moore CA, McCarthy K, Johnston B, Mohammed T, Vhembo T, Kabugho E, Muzorah GA, Cassim H, Fairlie L, Machado ES, Ngocho JS, Shapiro RL, Serghides L, Chakhtoura N, Chinula L, Lockman S. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants. J Infect Dis. 2024 Nov 15;230(5):1224-1234. doi: 10.1093/infdis/jiae308.
Chinula L, Ziemba L, Brummel S, McCarthy K, Coletti A, Krotje C, Johnston B, Knowles K, Moyo S, Stranix-Chibanda L, Hoffman R, Sax PE, Stringer J, Chakhtoura N, Jean-Philippe P, Korutaro V, Cassim H, Fairlie L, Masheto G, Boyce C, Frenkel LM, Amico KR, Purdue L, Shapiro R, Mmbaga BT, Patel F, van Wyk J, Rooney JF, Currier JS, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023 Jun;10(6):e363-e374. doi: 10.1016/S2352-3018(23)00061-9. Epub 2023 May 8.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form: IMPAACT 2010 Protocol V2.0
Document Type: Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 1
Document Type: Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 2
Document Type: Study Protocol: IMPAACT 2010 Protocol V2.0_Letter of Amendment 3
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Study website
The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017, was used
Intergrowth 21st Standards, including reference for infants small for gestational age
FDA Snapshot algorithm
Definition for major congenital anomalies
Schwartz formula for calculating infant creatinine clearance
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
30129
Identifier Type: REGISTRY
Identifier Source: secondary_id
IMPAACT 2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.